Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy

Future Oncol. 2014 Jan;10(1):107-22. doi: 10.2217/fon.13.168.

Abstract

Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6). Tamoxifen is a substrate for ATP-binding cassette transporter proteins. We review tamoxifen's clinical pharmacology and use meta-analyses to evaluate the clinical epidemiology studies conducted to date on the association between CYP2D6 inhibition and tamoxifen effectiveness. Our findings indicate that the effect of both drug-induced and/or gene-induced inhibition of CYP2D6 activity is likely to be null or small, or at most moderate in subjects carrying two reduced function alleles. Future research should examine the effect of polymorphisms in genes encoding enzymes in tamoxifen's complete metabolic pathway, should comprehensively evaluate other biomarkers that affect tamoxifen effectiveness, such as the transport enzymes, and focus on subgroups of patients, such as premenopausal breast cancer patients, for whom tamoxifen is the only guideline endocrine therapy.

Publication types

  • Meta-Analysis
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biological Transport
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Cytochrome P-450 CYP2D6 / genetics*
  • Cytochrome P-450 CYP2D6 / metabolism
  • Cytochrome P-450 CYP2D6 Inhibitors*
  • Female
  • Humans
  • Serotonin Uptake Inhibitors / pharmacology
  • Tamoxifen / metabolism*
  • Tamoxifen / pharmacokinetics*
  • Tamoxifen / pharmacology
  • Tamoxifen / therapeutic use
  • Treatment Outcome

Substances

  • Cytochrome P-450 CYP2D6 Inhibitors
  • Serotonin Uptake Inhibitors
  • Tamoxifen
  • Cytochrome P-450 CYP2D6